Results 31 to 40 of about 70,663 (209)

The application of CAR-T cell therapy in hematological malignancies: advantages and challenges

Acta Pharmaceutica Sinica B, 2018
Chimeric antigen receptor T cell (CAR-T cell) therapy is a novel adoptive immunotherapy where T lymphocytes are engineered with synthetic receptors known as chimeric antigen receptors (CAR).
Zijun Zhao, Yu Chen, Ngiambudulu M. Francisco, Yuanqing Zhang, Minhao Wu   +4 more
doaj   +1 more source

CAR-T Therapy in Lymphoma Patients With Coexisting Cardiomyopathy or Cardiac Lymphomatous Involvement

JACC: Case Reports, 2023
Chimeric antigen receptor T-cell (CAR-T) therapy has revolutionized the management of aggressive hematologic malignancies. However, its role in patients with lymphoma and cardiac metastasis or cardiomyopathy remains undefined due to potentially life ...
Choon Ta Ng, MBBS, Hilda M. Gonzalez Bonilla, MD, Ian Chang, MD, M. Tun Aung, MD, Jennifer J. Gile, MD, Naveen L. Pereira, MD, Jose C. Villasboas Bisneto, MD, Patrick B. Johnston, MD, Hector R. Villarraga, MD, Martin G. Rodriguez-Porcel, MD, Grace Lin, MD, Yi Lin, MD, PhD, Joerg Herrmann, MD   +12 more
doaj   +1 more source

Rejection of Experimental Hodgkins Lymphoma by T-cells Engineered with a CD19 Chimeric Antigen Receptor [PDF]

, 2012
T cells engineered to express chimeric receptors combining an external antibody binding domain with the CD3ζ T cell receptor (TCR) internal domain for triggering cell activation are being used for immunotherapeutic targeting of tumour cells in a non-HLA ...
Cheadle, Eleanor, Crawford, Dorothy, Gilham, David, Johannessen, Ingolfur, Swanson, Anna, Talbot, Simon   +5 more
core   +1 more source

Natural killer cell immunotherapy in glioblastoma

Discover Oncology, 2022
Glioblastoma (GBM) is one of the most difficult cancers to treat because GBM has the high therapeutic resistance. Recently, immunotherapies for GBM have been used instead of conventional treatments.
Hamed Hosseinalizadeh, Mehryar Habibi Roudkenar, Amaneh Mohammadi Roushandeh, Yoshikazu Kuwahara, Kazuo Tomita, Tomoaki Sato   +5 more
doaj   +1 more source

Early Investigations and Recent Advances in Intraperitoneal Immunotherapy for Peritoneal Metastasis. [PDF]

, 2018
Peritoneal metastasis (PM) is an advanced stage malignancy largely refractory to modern therapy. Intraperitoneal (IP) immunotherapy offers a novel approach for the control of regional disease of the peritoneal cavity by breaking immune tolerance.
Bowne, Wilbur B., Katz, Steven C., Khalili, Marian, Morano, William F., Richard, Scott D., Thadi, Anusha   +5 more
core   +2 more sources

Safety, tumor trafficking and immunogenicity of chimeric antigen receptor (CAR)-T cells specific for TAG-72 in colorectal cancer. [PDF]

, 2017
BackgroundT cells engineered to express chimeric antigen receptors (CARs) have established efficacy in the treatment of B-cell malignancies, but their relevance in solid tumors remains undefined.
A Molinolo, A Stasi Di, A Thor, B Fisher, BA Irving, BL Levine, C Romeo, CC Kloss, CY Wu, D Moritz, DL Porter, DW Lee, F Guadagni, HM Finney, I Blanco, I Stancovski, J Scholler, JD Wolchok, JL Murray, JN Kochenderfer, JW Greiner, KD Griffith, L Naldini, M Hegde, M Kalos, ME Dudley, MH Finer, MH Kershaw, ML Davila, MR Lander, N Gonzales, NP Restifo, P Hwu, RA Morgan, RE Walker, RF Meredith, RP McGuinness, RT Mitsuyasu, S Guedan, SD Patel, SG Deeks, SL Maude, SV Kashmiri   +42 more
core   +1 more source

Preclinical assessment of the efficacy and specificity of GD2-B7H3 SynNotch CAR-T in metastatic neuroblastoma

Nature Communications, 2021
Antibodies targeting a tumor antigen, GD2, show some efficacy for neuroblastoma but induce severe neuropathic pain and peripheral neuropathy. Here the authors design a gated chimeric antigen receptor (CAR), using GD2 as the gate and another tumor antigen,
Babak Moghimi, Sakunthala Muthugounder, Samy Jambon, Rachelle Tibbetts, Long Hung, Hamid Bassiri, Michael D. Hogarty, David M. Barrett, Hiroyuki Shimada, Shahab Asgharzadeh   +9 more
doaj   +1 more source

Targeting fibroblast activation protein in tumor stroma with chimeric antigen receptor T cells can inhibit tumor growth and augment host immunity without severe toxicity. [PDF]

, 2014
The majority of chimeric antigen receptor (CAR) T-cell research has focused on attacking cancer cells. Here, we show that targeting the tumor-promoting, nontransformed stromal cells using CAR T cells may offer several advantages.
Albelda, Steven M., Antzis, Michael, Cotner, Cody E., Durham, Amy C., Johnson, Laura A., June, Carl H., Kapoor, Veena, Lo, Albert, Majumdar, Rajrupa S., Puré, Ellen, Scholler, John, Solomides, MD, Charalambos C., Sun, Jing, Wang, Liang-Chuan S.   +13 more
core   +2 more sources

Evaluation of CAR-T cell cytotoxicity against a prostate carcinoma model

Учёные записки Казанского университета: Серия Естественные науки, 2022
In recent years, a new promising application of adoptive cell therapy (ACT) has been enabled by the development of technologies and the successful clinical use of T cells with a chimeric antigen receptor (CAR-T) for treating patients with malignant B ...
A.Kh. Valiullina, E.A. Zmievskaya, A.R. Rakhmatullina, M.N. Zhuravleva, E.E. Garanina, R.R. Miftakhova, A.V. Petukhov, A.A. Rizvanov, E.R. Bulatov   +8 more
doaj   +1 more source

CAR T Cells: Cancer Cell Surface Receptors Are the Target for Cancer Therapy [PDF]

Advanced Pharmaceutical Bulletin, 2022
Immunotherapy has become a prominent strategy for the treatment of cancer. A method thatimproves the immune system’s ability to attack a tumor (Enhances antigen binding).
Behrouz Shademan, Vahidreza Karamad, Alireza Nourazarian, Cigir Biray Avcı   +3 more
doaj   +1 more source